BAUDER-WUST; Ulrike

Patent Applications and Registrations

Patent applications and USPTO patent grants for BAUDER-WUST; Ulrike.The latest application filed is for "use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancer".

Company Profile

0.4.10

BAUDER-WUST; Ulrike - Schriesheim DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use Of Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), As Agents For The Treatment Of Prostate Cancer App 20210283279 - EDER; Matthias ; et al.	2021-09-16
Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer Grant 11,045,564 - Eder , et al. June 29, 2	2021-06-29
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma) As Agents For The Treatment Of Prostate Cancer App 20210177996 - EDER; Matthias ; et al.	2021-06-17
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The T App 20190374660 - EDER; Matthias ; et al.	2019-12-12
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer Grant 10,471,160 - Eder , et al. Nov	2019-11-12
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The T App 20190336622 - EDER; Matthias ; et al.	2019-11-07
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer Grant 10,398,791 - Eder , et al. Sep	2019-09-03
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer App 20190060491 - EDER; Matthias ; et al.	2019-02-28
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer App 20190008988 - EDER; Matthias ; et al.	2019-01-10
18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer Grant 10,016,519 - Kopka , et al. July 10, 2	2018-07-10
18f-tagged Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer App 20170246327 - KOPKA; Klaus ; et al.	2017-08-31
Labeled Inhibitors Of Prostate Specific Membrane Antigen (psma), Their Use As Imaging Agents And Pharmaceutical Agents For The Treatment Of Prostate Cancer App 20160228587 - EDER; Matthias ; et al.	2016-08-11
Diagnostic Agents For Positron Emission Imaging Using F-18 Radio-labeled Amino-alcohols App 20090130020 - Lehmann; Lutz ; et al.	2009-05-21
Polyamine-substituted ligands for use as contrast agents App 20070202047 - Wolf; Markus ; et al.	2007-08-30

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.